Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.41 |
| ▸ | BTK | Q06187 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.40 |
| ▸ | KDM5A | P29375 | 1/20 | 0.40 |
| ▸ | HCRTR2 | O43614 | 5/20 | 0.40 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.40 |
| ▸ | FURIN | P09958 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22866415 | 1.00 | NAAA (0.47) | NAAAEPHX2KCNH2OPRK1HRH3 | |
| SCHEMBL22866416 | 1.00 | NAAA (0.47) | NAAAEPHX2KCNH2OPRK1HRH3 | |
| SCHEMBL22174122 | 1.00 | NAAA (0.47) | NAAAEPHX2KCNH2OPRK1HRH3 | |
| SCHEMBL22174115 | 0.84 | EPHX2 (0.40) | EPHX2KCNH2OPRK1BTKGPR119 | |
| SCHEMBL22196921 | 0.84 | EPHX2 (0.40) | EPHX2KCNH2OPRK1BTKGPR119 | |
| SCHEMBL20958452 | 0.84 | NAAA (0.51) | NAAAEPHX2KCNH2OPRK1HRH3 | |
| SCHEMBL20958454 | 0.84 | NAAA (0.51) | NAAAEPHX2KCNH2OPRK1HRH3 | |
| SCHEMBL1165320 | 0.84 | NAAA (0.51) | NAAAEPHX2KCNH2OPRK1HRH3 | |
| SCHEMBL1165321 | 0.84 | NAAA (0.51) | NAAAEPHX2KCNH2OPRK1HRH3 | |
| SCHEMBL22196870 | 0.79 | BTK (0.52) | EPHX2HRH3BTKKDM5AHCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11771689-B2 | Cereblon modulators and uses thereof | VIVIDION THERAPEUTICS, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-20220298213-A1 | IN VIVO ENGINEERED CEREBLON PROTEIN | VIVIDION THERAPEUTICS, INC. | 2022-09-22 | — | — | US | disclosed |
| US-10869860-B2 | Cereblon modulators and uses thereof | VIVIDION THERAPEUTICS, INC. (US) | 2020-12-22 | — | — | US | disclosed |
| US-10781239-B2 | In vivo engineered cereblon protein | VIVIDION THERAPEUTICS, INC. (US) | 2020-09-22 | — | — | US | disclosed |
| US-20200216507-A1 | IN VIVO ENGINEERED CEREBLON PROTEIN | VIVIDION THERAPEUTICS, INC. | 2020-07-09 | — | — | US | disclosed |
| US-20200206201-A1 | CEREBLON MODULATORS AND USES THEREOF | VIVIDION THERAPEUTICS, INC. | 2020-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220298213-A1 | IN VIVO ENGINEERED CEREBLON PROTEIN | CRBN, CDR2, DCUN1D4 | NAAA 3516/4885EPHX2 2130/4885KCNH2 4601/4885 |
| US-20200216507-A1 | IN VIVO ENGINEERED CEREBLON PROTEIN | CRBN, CDR2, DCUN1D4 | NAAA 3516/4885EPHX2 2130/4885KCNH2 4601/4885 |
| US-11771689-B2 | Cereblon modulators and uses thereof | CRBN, CBFB, CNN2 | NAAA 2739/4885EPHX2 2655/4885KCNH2 4449/4885 |
| US-10869860-B2 | Cereblon modulators and uses thereof | CRBN, CBFB, CNN2 | NAAA 2739/4885EPHX2 2655/4885KCNH2 4449/4885 |
| US-20200206201-A1 | CEREBLON MODULATORS AND USES THEREOF | CRBN, CBFB, CNN2 | NAAA 2739/4885EPHX2 2655/4885KCNH2 4449/4885 |
| US-10781239-B2 | In vivo engineered cereblon protein | CRBN, CDR2, DCUN1D4 | NAAA 3516/4885EPHX2 2130/4885KCNH2 4601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.